Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Danish pharma giant Novo Nordisk has reported promising data on its new weight loss pill, which has been shown to lower body ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 9 trades. If we consider the specifics of ...